AKT1 and cancer: Interestingly p-PRAS40, another AKT substrate, was constitutively expressed in apalutamide-treated CRPC, regardless of nuclear AR status, and while p-STAT3 expression in cancer cells generally remained low in areas corresponding to nuclear AR, the proportion of strong-positive p-STAT3py705 tended to be greater in regions with low nuclear AR (Figure 4D).